GoAI
Get started
CVRx, Inc. logo

CVRx, Inc.

CVRX

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$2.84

$0.00 · 0.00%

Aug 21, 4:00 PM ET

CVRX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

74

Undervalued

Momentum

22

Weakening

Sentiment

49

Mixed

Risk resilience

33

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Kevin Hykes
Listed since
Jun 30, 2021
Employees
223

Market position

Day range

Current $2.84

52-week range

Current $2.84

Open
$2.86
Previous close
$2.84
Volume
742.07K
1.28× average
Average volume
580.4K
Average daily volume
Market cap
75.36M USD
Beta
0.82
Market reference 1
50-day average
$4.677
-39.28% below average
200-day average
$6.8359
-58.45% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
160.28M USD
P/E (TTM)
-1.43×
P/B (TTM)
3.77×
P/S (TTM)
1.23×
EV / EBITDA
-3.43×
Earnings yield
-28.78%
Free cash flow yield
-22.00%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
86.60%
Operating margin
-79.49%
Net margin
-84.93%
Return on equity
-135.56%
Return on assets
-50.87%
Return on invested capital
-56.02%

Financial health

Debt / equity
2.98×
Current ratio
7.63×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends127%-39%-206%-372%Gross margin, FY2021: 72.08%Gross margin, FY2022: 77.75%Gross margin, FY2023: 84.08%Gross margin, FY2024: 83.75%Gross margin, FY2025: 85.33%Operating margin, FY2021: -199.20%Operating margin, FY2022: -189.27%Operating margin, FY2023: -109.69%Operating margin, FY2024: -115.98%Operating margin, FY2025: -90.49%Net margin, FY2021: -330.45%Net margin, FY2022: -184.38%Net margin, FY2023: -104.85%Net margin, FY2024: -116.91%Net margin, FY2025: -94.10%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 72.08%. Gross margin FY2022 77.75%. Gross margin FY2023 84.08%. Gross margin FY2024 83.75%. Gross margin FY2025 85.33%. Operating margin FY2021 -199.20%. Operating margin FY2022 -189.27%. Operating margin FY2023 -109.69%. Operating margin FY2024 -115.98%. Operating margin FY2025 -90.49%. Net margin FY2021 -330.45%. Net margin FY2022 -184.38%. Net margin FY2023 -104.85%. Net margin FY2024 -116.91%. Net margin FY2025 -94.10%.

Income trends

Revenue

56.65M USD+10.45%

Operating income

−51.27M USD+13.83%

Net income

−53.31M USD+11.10%
Income trends across reported periods68.31M USD21.67M USD−24.98M USD−71.63M USDRevenue, FY2021: 13.04M USDRevenue, FY2022: 22.47M USDRevenue, FY2023: 39.3M USDRevenue, FY2024: 51.29M USDRevenue, FY2025: 56.65M USDOperating income, FY2021: −25.97M USDOperating income, FY2022: −42.53M USDOperating income, FY2023: −43.1M USDOperating income, FY2024: −59.49M USDOperating income, FY2025: −51.27M USDNet income, FY2021: −43.08M USDNet income, FY2022: −41.43M USDNet income, FY2023: −41.2M USDNet income, FY2024: −59.97M USDNet income, FY2025: −53.31M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 13.04M USD. Revenue FY2022 22.47M USD. Revenue FY2023 39.3M USD. Revenue FY2024 51.29M USD. Revenue FY2025 56.65M USD. Operating income FY2021 −25.97M USD. Operating income FY2022 −42.53M USD. Operating income FY2023 −43.1M USD. Operating income FY2024 −59.49M USD. Operating income FY2025 −51.27M USD. Net income FY2021 −43.08M USD. Net income FY2022 −41.43M USD. Net income FY2023 −41.2M USD. Net income FY2024 −59.97M USD. Net income FY2025 −53.31M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue56.65M USD51.29M USD39.3M USD22.47M USD13.04M USD
Cost of goods sold8.31M USD8.33M USD6.26M USD5M USD3.64M USD
Gross profit48.34M USD42.96M USD33.04M USD17.47M USD9.4M USD
Research and development11.13M USD11.13M USD11.63M USD9.95M USD7.5M USD
Selling, general, and administrative88.47M USD91.32M USD64.51M USD50.05M USD27.86M USD
Operating expenses99.61M USD102.45M USD76.14M USD60M USD35.36M USD
Interest expense5.83M USD4.4M USD1.8M USD165K USD2.22M USD
Depreciation and amortization756K USD619K USD522K USD412K USD168K USD
Operating income−51.27M USD−59.49M USD−43.1M USD−42.53M USD−25.97M USD
Net income−53.31M USD−59.97M USD−41.2M USD−41.43M USD−43.08M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

7 ratings
Strong buy00%
Buy571%
Hold114%
Sell114%
Strong sell00%

CVRX news

prnewswire.com

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

SAN FRANCISCO, Aug. 19, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal…

Read source
newsfilecorp.com

CVRx, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

Boston, Massachusetts--(Newsfile Corp. - August 18, 2026) - Block & Leviton is investigating CVRx, Inc. (NASDAQ: CVRX) for potential securities law violations. Investors who have lost money in their CVRx, Inc. investment…

Read source
globenewswire.com

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of…

Read source
newsfilecorp.com

CVRX ALERT: Securities Fraud Investigation by Block & Leviton Could Allow CVRx, Inc. Investors to Recover Losses

Boston, Massachusetts--(Newsfile Corp. - August 13, 2026) - Block & Leviton is investigating CVRx, Inc. (NASDAQ: CVRX) for potential securities law violations. Investors who have lost money in their CVRx, Inc. investment…

Read source
marketbeat.com

CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches

CVRx NASDAQ: CVRX outlined its efforts to expand adoption of its Barostim therapy for heart failure patients, emphasizing sales-force execution, payer coverage progress and a large post-market clinical trial during…

Read source
businesswire.com

Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) on behalf of investors concerning the Company's possible violations of…

Read source

CVRX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CVRX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3.54M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.06M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
1.04M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
446.52K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
443.05K
Weight
0.00%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
148.46K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
89.77K
Weight
0.01%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$282.73+1.21%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
37.51K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%

Continue in GoAI

Research CVRX

research.disclaimer